C M Perks
Overview
Explore the profile of C M Perks including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
751
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Biernacka K, Barker R, Sewell A, Bahl A, Perks C
Transl Oncol
. 2023 Jun;
34:101698.
PMID: 37307644
Prostate cancer (PCa) is one of the leading causes of cancer-related deaths in men. Localised PCa can be treated effectively, but most patients relapse/progress to more aggressive disease. One possible...
2.
Zielinska H, Holly J, Bahl A, Perks C
Cancer Lett
. 2018 Jan;
419:187-202.
PMID: 29331414
Since disturbed metabolic conditions such as obesity and diabetes can be critical determinants of breast cancer progression and therapeutic failure, we aimed to determine the mechanism responsible for their pro-oncogenic...
3.
Biernacka K, Persad R, Bahl A, Gillatt D, Holly J, Perks C
Endocr Relat Cancer
. 2016 Oct;
24(1):17-30.
PMID: 27754854
The incidence of many common cancers varies between different populations and appears to be affected by a Western lifestyle. Highly proliferative malignant cells require sufficient levels of nutrients for their...
4.
Zeng L, Zielinska H, Arshad A, Shield J, Bahl A, Holly J, et al.
Endocr Relat Cancer
. 2015 Dec;
23(2):125-34.
PMID: 26647383
Breast cancer patients with diabetes respond less well to chemotherapy; in keeping with this we determined previously that hyperglycaemia-induced chemoresistance in estrogen receptor (ERα) positive breast cancer cells and showed...
5.
Biernacka K, Uzoh C, Zeng L, Persad R, Bahl A, Gillatt D, et al.
Endocr Relat Cancer
. 2013 Aug;
20(5):741-51.
PMID: 23959956
Clinically relevant prostate cancer (PCa) is more frequent in Westernised societies and increasingly men have co-morbidities associated with a Western lifestyle, primarily diabetes, characterised by hyperinsulinaemia and hyperglycaemia. IGFs and...
6.
Hale L, Welsh G, Perks C, Hurcombe J, Moore S, Hers I, et al.
J Pathol
. 2013 Jan;
230(1):95-106.
PMID: 23299523
Podocytes are crucial for preventing the passage of albumin into the urine and, when lost, are associated with the development of albuminuria, renal failure and cardiovascular disease. Podocytes have limited...
7.
Biernacka K, Perks C, Holly J
Minerva Endocrinol
. 2012 Jun;
37(2):173-85.
PMID: 22691890
The major issue currently being faced in the management of prostate cancer is the inability to distinguish between indolent prostate tumors that will not present clinically from more aggressive and...
8.
Ammoun S, Schmid M, Zhou L, Ristic N, Ercolano E, Hilton D, et al.
Oncogene
. 2011 Sep;
31(13):1710-22.
PMID: 21892205
Merlin is a tumour suppressor involved in the development of a variety of tumours including mesotheliomas. Neurofibromatosis type 2 (NF2), a dominantly inherited tumour disease, is also caused by loss...
9.
Uzoh C, Holly J, Biernacka K, Persad R, Bahl A, Gillatt D, et al.
Br J Cancer
. 2011 Apr;
104(10):1587-93.
PMID: 21487405
Background: The development of androgen independence, chemo-, and radioresistance are critical markers of prostate cancer progression and the predominant reasons for its high mortality. Understanding the resistance to therapy could...
10.
Zeng L, Biernacka K, Holly J, Jarrett C, Morrison A, Morgan A, et al.
Endocr Relat Cancer
. 2010 Apr;
17(2):539-51.
PMID: 20356977
The prognosis for women with breast cancer is adversely affected by the comorbidities of obesity and diabetes mellitus (DM), which are conditions associated with elevated levels of circulating fatty acids,...